PHARMACOKINETICS OF PEGLOTICASE AND METHOTREXATE POLYGLUTAMATE(S) IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING PEGLOTICASE AND CO-TREATMENT OF METHOTREXATE

被引：1
|
作者：
Song, Y. [1 ]
Xin, Y. [1 ]
Weinblatt, M. E. [2 ]
Chamberlain, J. [1 ]
Obermeyer, K. [3 ]
Zhao, L. [3 ]
Canavan, C. [3 ]
Peloso, P. M. [3 ]
Ramanathan, S. [1 ]
机构：
[1] Horizon Therapeut Plc, Res & Dev, San Francisco, CA USA
[2] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA
[3] Horizon Therapeut Plc, Res & Dev, Deerfield, IL USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.2136
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1136
引用
收藏
页码：847 / 848
页数：2
相关论文
共 50 条
  • [21] Baseline Renal Characteristics and Trial Design for MIRROR RCT, Randomized Trial of Pegloticase with or Without Methotrexate for Uncontrolled Gout
    Botson, John K.
    Parikh, Naval G.
    Ong, Stephen
    La, Dan T.
    Locicero, Karon
    Peterson, Jeff R.
    Grewal, Suneet
    Peloso, Paul M.
    Sainati, Stephen M.
    Obermeyer, Katie L.
    Saag, Kenneth G.
    Tesser, John
    Majjhoo, Amar Q.
    Weinblatt, Michael E.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 852 - 852
  • [22] Pegloticase for Uncontrolled Gout in Patients with History of Kidney Transplant: Pharmacokinetics and Immunogenicity in the PROTECT Clinical Trial
    Abdellatif, Abdul
    Xin, Yan
    Chamberlain, Jason
    Zhao, Lin
    Cherny, Katya
    Marder, Brad
    Scandling, John D.
    saag, Kenneth
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3588 - 3589
  • [23] Intensive urate-lowering with pegloticase plus methotrexate co-therapy in uncontrolled gout patients with and without chronic kidney disease: A retrospective case series
    Albert, John
    Broadwell, Aaron
    Padnick-Silver, Lissa
    Marder, Brad
    LaMoreaux, Brian
    MEDICINE, 2024, 103 (10) : E37424
  • [24] PATIENT REPORTED OUTCOMES AMONG PATIENTS RECEIVING TREATMENT FROM THE PEGLOTICASE PHASE 3 CLINICAL TRIALS FOR UNCONTROLLED GOUT
    Sparks, J.
    Obermeyer, K.
    Lamoreaux, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1643 - 1643
  • [25] Safety, Tolerability and Efficacy of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrolled Gout Receiving Methotrexate: Primary Findings of the AGILE Open-label Trial
    Troum, Orrin
    Botson, John
    Fang, Fang
    Obermeyer, Katie
    Verma, Supra
    LaMoreaux, Brian
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4089 - 4090
  • [26] A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study
    Botson, John
    Peloso, Paul
    Obermeyer, Katie
    LaMoreaux, Brian
    Zhao, Lin
    Weinblatt, Michael
    Peterson, Jeff
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [27] Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout
    Aaron Broadwell
    John A. Albert
    Lissa Padnick-Silver
    Brian LaMoreaux
    Rheumatology and Therapy, 2022, 9 : 1549 - 1558
  • [28] Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study
    Karim Richard Masri
    Lissa Padnick-Silver
    Kevin Winterling
    Brian LaMoreaux
    Rheumatology and Therapy, 2022, 9 : 555 - 563
  • [29] Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study
    Masri, Karim Richard
    Padnick-Silver, Lissa
    Winterling, Kevin
    LaMoreaux, Brian
    RHEUMATOLOGY AND THERAPY, 2022, 9 (02) : 555 - 563
  • [30] Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout
    Broadwell, Aaron
    Albert, John A.
    Padnick-Silver, Lissa
    LaMoreaux, Brian
    RHEUMATOLOGY AND THERAPY, 2022, 9 (06) : 1549 - 1558
12345